A Study of LY2940680 in Healthy Participants
Condition: Healthy Participants
Intervention: LY2940680 Capsule(s) (Reference); LY2940680 Tablet (Test); Lansoprazole; Placebo Capsule(s)
Intervention description: Administered orally as a capsule(s); Administered orally as a tablet; Administered orally as a capsule; Administered orally as a capsule(s)
Intervention MeSH terms: Lansoprazole; Dexlansoprazole
Phase: Phase 1
Study type: Interventional
Primary purpose: Other
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Double (Participant, Investigator)
Enrollment: 30.0
Sex: All
Minimum age: 18 Years
Maximum age: 65 Years
Healthy volunteers: Accepts Healthy Volunteers

Summary:

      This study involves 2 parts, Part A and Part B. The purpose of Part A is to evaluate the
      safety and side effects of LY2940680 in healthy participants. Part A will involve two groups
      of participants, each taking up to two single doses of LY2940680 at different dose levels.
      There is a minimum 14 day washout period between each of the participant's doses. The purpose
      of Part B is to study how much of the study drug, in capsule or tablet form, gets into the
      bloodstream and how long the body takes to get rid of it. In addition, the effect of food and
      a proton pump inhibitor (PPI) on LY2940680 will be studied. Part B will involve one group of
      participants who will take four single doses of 100 milligrams (mg) LY2940680. There is a
      minimum 7 day washout period between doses. Participants may only enroll in one part.
      Screening is required within 28 days prior to the start of the study.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Healthy sterile males or surgically sterile females or postmenopausal females, as
             determined by medical history and physical examination

          -  Body mass index of 18.5 to 32.0 kilograms per meter square (kg/m^2)

          -  Have clinical laboratory test results within normal reference range

          -  Have given written informed consent approved by Lilly and the ethical review board
             (ERB) governing the site

          -  Prepared to eat an entire high fat breakfast

        Exclusion Criteria:

          -  Are currently enrolled in, have completed or discontinued within the last 30 days from
             a clinical trial involving an investigational product

          -  Have known allergies to LY2940680, related compounds or any components of the
             formulation, or known allergies to lansoprazole (Part B only)

          -  Have previously completed or withdrawn from this study or any other study
             investigating LY2940680, and have previously received the investigational product.
             Participants in Part A are not allowed to participate in Part B

          -  Have an abnormality in the 12-lead electrocardiogram (ECG)

          -  Have a history of or current cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders capable of
             significantly altering the absorption, metabolism, or elimination of drugs; of
             constituting a risk when taking the study medication; or of interfering with the
             interpretation of data (cholecystectomy or appendectomy are allowed if surgery at
             least 6 months prior to screening)

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening

          -  Show evidence of human immunodeficiency virus (HIV) infection and/or positive human
             HIV antibodies

          -  Show evidence of hepatitis C and/or positive hepatitis C antibody

          -  Show evidence of hepatitis B and/or positive hepatitis B surface antigen

          -  Have used or intend to use over-the-counter or prescription medication within 14 days
             prior to dosing or during the study. Exception: participants may continue hormone
             replacement therapy (HRT; estrogen)

          -  Use of herbal supplements, grapefruit juice, grapefruits, Seville orange juice,
             Seville oranges, or Starfruit within 7 days prior to dosing or during the study